These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10023952)

  • 1. Cirrhosis with steatohepatitis after adjuvant tamoxifen.
    Oien KA; Moffat D; Curry GW; Dickson J; Habeshaw T; Mills PR; MacSween RN
    Lancet; 1999 Jan; 353(9146):36-7. PubMed ID: 10023952
    [No Abstract]   [Full Text] [Related]  

  • 2. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis.
    Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
    Lancet; 1999 May; 353(9166):1802. PubMed ID: 10348023
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen].
    Dray X; Tainturier MH; De La Lande P; Marty O; Mallet L
    Gastroenterol Clin Biol; 2000 Nov; 24(11):1122-3. PubMed ID: 11139682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen-induced cirrhotic process.
    Kotiloglu G; Aki ZS; Ozyilkan O; Kutlay L
    Breast J; 2001; 7(6):442-3. PubMed ID: 11843860
    [No Abstract]   [Full Text] [Related]  

  • 5. Fatty liver and transaminase changes with adjuvant tamoxifen therapy.
    Liu CL; Huang JK; Cheng SP; Chang YC; Lee JJ; Liu TP
    Anticancer Drugs; 2006 Jul; 17(6):709-13. PubMed ID: 16917217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen-induced fatty liver in patients with breast cancer.
    Ogawa Y; Murata Y; Nishioka A; Inomata T; Yoshida S
    Lancet; 1998 Mar; 351(9104):725. PubMed ID: 9504521
    [No Abstract]   [Full Text] [Related]  

  • 7. [A case of steatohepatitis associated with tamoxifen].
    Kanda T; Yokosuka O; Chiba T; Kojima H; Fukai K; Imazeki F; Saisho H
    Nihon Shokakibyo Gakkai Zasshi; 2002 Sep; 99(9):1119-21. PubMed ID: 12355903
    [No Abstract]   [Full Text] [Related]  

  • 8. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
    Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
    Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
    Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S
    Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen-induced transient multifocal hepatic fatty infiltration.
    Cai Q; Bensen M; Greene R; Kirchner J
    Am J Gastroenterol; 2000 Jan; 95(1):277-9. PubMed ID: 10638597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic steatohepatitis.
    Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
    Lancet; 1999 Oct; 354(9186):1299-300. PubMed ID: 10520659
    [No Abstract]   [Full Text] [Related]  

  • 12. Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist.
    Ahmed MH; Osman KA
    Breast Cancer Res Treat; 2006 May; 97(2):223-4. PubMed ID: 16322887
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer.
    Akhondi-Meybodi M; Mortazavy-Zadah MR; Hashemian Z; Moaiedi M
    Arab J Gastroenterol; 2011 Mar; 12(1):34-6. PubMed ID: 21429453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen-induced submassive hepatic necrosis.
    Storen EC; Hay JE; Kaur J; Zahasky K; Hartmann L
    Cancer J; 2000; 6(2):58-60. PubMed ID: 11069218
    [No Abstract]   [Full Text] [Related]  

  • 15. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
    Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U
    BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy.
    Nishino M; Hayakawa K; Nakamura Y; Morimoto T; Mukaihara S
    AJR Am J Roentgenol; 2003 Jan; 180(1):129-34. PubMed ID: 12490491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tamoxifen; wider indications, more frequent controls?].
    Mourits MJ; van der Zee AG; Willemse PH; de Vries EG
    Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1766-7. PubMed ID: 11572184
    [No Abstract]   [Full Text] [Related]  

  • 18. Tamoxifen-induced fatty liver disease in a Caucasian patient.
    Eechoute K; Mathijssen RHJ; van Gelder T
    Breast Cancer Res Treat; 2018 Aug; 171(1):243-244. PubMed ID: 29736740
    [No Abstract]   [Full Text] [Related]  

  • 19. Occurrence of stroke with tamoxifen in NSABP B-24.
    Dignam JJ; Fisher B
    Lancet; 2000 Mar; 355(9206):848-9. PubMed ID: 10711957
    [No Abstract]   [Full Text] [Related]  

  • 20. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance.
    Elefsiniotis IS; Pantazis KD; Ilias A; Pallis L; Mariolis A; Glynou I; Kada H; Moulakakis A
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):593-8. PubMed ID: 15167162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.